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Background. Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplanta-
tion (HSCT), and updated epidemiological investigation is advisable.
Methods. We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 
autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression 
methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. 
Results. The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with 
GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration 
of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pre-
transplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same 
microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of 
infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months 
both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45–3.13; P <.001) and auto-HSCT (2.43; 1.22–4.84; P = .01).
Conclusions. Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-
HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB.
Clinical Trials registration. NCT02088840.
Keywords. stem cell transplant; Gram negative bacteremia; multidrug resistance; epidemiology; survival.
 
Gram-negative bacteremia (GNB) is a leading cause of illness 
and death after hematopoietic stem cell transplantation 
(HSCT) [1–9]. Challenges include the changes in GNB inci-
dence, susceptibility patterns to antibiotics and prognosis 
due to changes in transplant populations, the global epide-
miology of infections, and antimicrobial strategies. Because 
of the poor outcomes associated with GNB in transplant 
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recipients, there is much interest in the identification of risk 
and prognostic factors, which may help determine tailored 
infection-control strategies [4–10]. Therefore, updated epi-
demiological investigation in this population is advisable.
To assess the incidence, risk and prognostic factors of pre-en-
graftment GNB in HSCT recipients, data from patients under-
going allogeneic HSCT (allo-HSCT) and autologous HSCT 
(auto-HSCT) during 2014 were prospectively registered. These 
data provide the basis for promoting direct efforts in risk strati-
fication, prevention, and management of gram-negative bacter-
ial infections in the HSCT population.
METHODS
Study Design
The Severe Infections by Gram-Negative Bacteria (SIGNB) study 
was sponsored by the Italian Stem cell Transplantation Network 
(Gruppo Italiano Trapianto di Midollo Osseo [GITMO]) and 
the Italian Association of Clinical Microbiologists (Associazione 
Microbiologi Clinici Italiani [AMCLI]). The SIGNB-GITMO-
AMCLI study was a prospective epidemiological survey per-
formed in 54 transplant centers in Italy between 1 January and 
31 December 2014. Study start times could differ among centers, 
but all consecutive transplants were enrolled. The results of this 
study were reported according to the STROBE (STrengthening 
the Reporting of OBservational studies in Epidemiology) state-
ment [11]. The study was approved by the ethical committee 
of each center, and informed consent was obtained from the 
patients.
Data Collection
Variables included patients characteristics, diagnosis and phase 
of the underlying disease, prior auto-HSCT or allo-HSCT, neu-
tropenia within 30 days before HSCT, GNB documented within 
3 months before HSCT, stem cell donor, stem cell source, pre-
transplant conditioning regimen, the use of “in vivo” T-cell 
depletion with antithymocyte globulin or cell manipulation ex 
vivo, antibacterial prophylaxis during the neutropenia period, 
colonization by resistant gram-negative bacteria at the pre-
transplant screening and during pre-engraftment, develop-
ment of grade II–IV mucositis, duration of pre-engraftment 
neutropenia, development of grade II–IV acute graft-vs-host 
disease (GVHD) before engraftment, microbiologically doc-
umented bacterial and fungal infections, viral diseases and 
clinically documented infections before engraftment, survival 
at 4 months after HSCT, and cause of death. Information per-
taining to the GNB included timing after HSCT and in vitro 
susceptibility.
Definition of Infection and Colonization
All cases of GNB with microorganism isolation from ≥1 blood 
culture were considered. For each isolate in vitro susceptibility 
data included sensitivity or nonsensitivity to the third-genera-
tion cephalosporin ceftazidime (ceph-S or ceph-NS) and sensi-
tivity or nonsensitivity to carbapenems (carba-S or carba-NS) 
for enterobacteria (defined as a minimum inhibitory concen-
tration >1 mg/L for imipenem, meropenem, and/or ertapenem) 
and multidrug resistance (MDR) for gram-negative nonfer-
menters (defined as resistance to ≥3 antimicrobial groups 
among piperacillin-tazobactam, ceftazidime, fluoroquinolones, 
aminoglycosides, and carbapenems).
The investigators were also asked whether their center rou-
tinely performed pre- and posttransplant surveillance of colo-
nization by ceph-NS enterobacteria, carba-NS enterobacteria, 
and MDR nonfermenters, using culture of rectal/perianal swab 
samples, and reported the cases of colonization. Therefore, for 
the colonization analysis, we excluded patients who did not 
undergo such screening.
Analyses
The analyses were performed separately for auto-HSCT and 
allo-HSCT. The cumulative incidence of pre-engraftment GNB 
was calculated, accounting for the competing risks of infec-
tion-free death. Cumulative incidence of GNB was calculated 
for any type and status of the underlying disease, stem cell 
donor, stem cell source, pretransplant conditioning, history of 
GNB before transplant, antibacterial prophylaxis, and acute 
GVHD. Considering the different times of engraftment for the 
2 transplant procedures, we calculated the cumulative incidence 
of GNB 20 days after auto-HSCT and 30 days after allo-HSCT. 
All factors were evaluated in multivariate models to control 
potential confounders using logistic regression methods.
Survival analyses were performed according to the above 
variables. Deaths were attributed to GNB in patients who 
failed to respond to therapy (ie, who had unstable disease or 
disease progression, according to the responsible physician 
judge) and in patients with a partial response to therapy who 
died because of an acute event involving any of the sites of 
infection and in the absence of other causes thought to have 
primarily contributed to death. The probability of 4-month 
survival after HSCT was calculated using Kaplan-Meier esti-
mates, log-rank tests were applied for univariate analysis, and 
2-sided P values ≤.05 were considered to represent statistical 
significance. Multivariate analyses were performed using a 
Cox proportional hazards regression model. In this model, 
variables related to GNB and acute GVHD were considered as 
time-dependent covariates in order to evaluate their effect only 
in the period after their onset. All significant variables in the 
univariate analysis were included in the multivariate analysis; 
final models were also evaluated with backward and stepwise 
function. Statistical analyses were performed using SAS soft-
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RESULTS
Patient Characteristics
Overall, 1118 allo-HSCTs from 44 centers (median per center, 
20; range, 2–105) and 1625 auto-HSCTs from 52 centers (23; 
4–101) were included in the study. Demographics and patient 
characteristics at HSCT are shown in Table 1. Most allo-HSCT 
and auto-HSCT recipients were affected by acute leukemia 
(65%) and multiple myeloma (52%), respectively. The vast 
majority of allo-HSCTs (74%) involved transplants from an 
HLA-mismatched related or unrelated donor.
Allo-Hematopoietic Stem Cell Transplantation
Pre-engraftment Infections and Details on Gram-Negative 
Bacteremia
The infections documented before engraftment are detailed in 
Table 2. Overall, 149 GNBs were documented in 140 of 1118 
allo-HSCTs (12.5%). The rate of GNBs by transplant center 
ranged from 0% to 39.1% (median, 11.7%). The median rate 
of GNB accounted for 11.1% in centers with lower transplant 
activity (≤20 HSCTs) and 13.2% in those with higher activity 
(>20 HSCTs) (P = .82). Escherichia coli was the most com-
mon gram-negative pathogen (77 cases; 51.7%), followed by 
Klebsiella pneumoniae (28 cases; 18.8%) and Pseudomonas 
aeruginosa (21 cases; 14.1%). The susceptibility pattern of the 
isolates is detailed in Table 3.
Risk Factors for Gram-Negative Bacteremia in Allo-Hematopoietic 
Stem Cell Transplantation Recipients
The cumulative incidence of GNB 30  days after allo-HSCT 
was 17.3% (95% confidence interval [CI], 12.5%–22.7%) 
(Figure  1A). GNB-free pre-engraftment death occurred in 25 
HSCT recipients (2.2%). The risk of GNB according to demo-
graphics, underlying disease, and transplant variables are 
detailed in Table 4. By multivariate analysis, variables associated 
with increased risk of pre-engraftment GNB were acute leu-
kemia, a transplant from an HLA-mismatched donor (related 
or unrelated) and from cord blood, older recipient age, and 
duration of severe neutropenia (polymorphonuclear leukocyte 
count <100/μL), and ex vivo graft manipulation was protective 
against GNB.
Risk of Gram-Negative Bacteremia According to Pretransplant 
Infection and Colonization
A pretransplant bloodstream infection by ≥1 gram-negative 
pathogen (88 isolates) was reported in 84 patients (7.5%) (ceph-S 
E. coli in 17, ceph-NS/carba-S E. coli in 17, ceph-S K. pneumoniae 
in 4, ceph-NS/carba-S K. pneumoniae in 9, carba-NS K. pneu-
moniae in 6, non-MDR P. aeruginosa in 11, MDR P. aeruginosa 
in 4, Enterobacter cloacae complex in 6, and other pathogens in 
14). An infection by the same species with the same susceptibil-
ity phenotype was documented in 16 of these 84 patients (19%) 
a median of 7 days (range, 1–25 days) after transplant (ceph-S 







Age, median (range), y 44 (1–72) 56 (1–75)
Pediatric patients (age ≤18 y) 224 (20) 92 (5.7)
Male sex 652 (58.3) 958 (58.9)
Underlying disease
 Acute myeloid leukemia 420 (37.6) 47 (2.9)
 Acute lymphoid leukemia 205 (18.3) 15 (0.9)
 Other acute leukemias 6 (0.5) 0
 Myelodysplastic syndromes 96 (8.6) 1 (<0.1)
 Chronic myeloproliferative 64 (5.7) 2 (0.1)
 Non-Hodgkin lymphoma 99 (8.8) 432 (26.6)
 Hodgkin lymphoma 66 (5.9) 168 (10.3)
 Chronic lymphoid leukemia 14 (1.2) 3 (0.2) 
 Multiple myeloma, plasmacellular leukemia, 
amyloidosis
59 (5.3) 846 (52.1)
 Aplastic anemia 34 (3.0) 0
 Hemoglobinopathy 28 (2.4) 0
 Solid tumors 4 (0.4) 88 (5.4)
 Other diseases 23 (2.1) 23 (1.4)
Phase of underlying disease at transplant
 Cancer in complete remission 617 (55.2) 668 (41.1)
 Cancer not in complete remission/active 416 (37.2) 934 (57.5)
 Nonmalignant stable/chronic diseases 85 (7.6) 23 (1.4)
Previous HSCT
 Auto-HSCT alone 204 (18.2) 343 (21.1)
 Allo-HSCT alone 90 (8.0) 2 (0.1)
 Auto- and allo-HSCT 15 (1.3) 1 (<0.1)
Donor type
 HLA matched, related 296 (26.5) NA
 HLA mismatched, relatedb 352 (31.5) NA
 HLA matched, unrelated volunteer 295 (26.4) NA
 HLA mismatched unrelated volunteer 145 (13.0) NA
 Unrelated cord blood 30 (2.7) NA
Stem cell source
 Bone marrow 476 (42.6) 9 (0.5)
 Peripheral blood 612 (54.7) 1616 (99.5)
 Cord blood 30 (2.7) 0
Pretransplant conditioning
 Myeloablative 826 (73.9) 1472 (90.6)
 Reduced intensity 251 (22.4) 32 (2.0)
 Nonmyeloablative 41 (3.7) 121 (7.4)
T-cell depletion
 No 636 (56.9) 1625 (100)
 Yes, in vivo (ATG or alemtuzumab) 386 (34.5) 0
 Yes, ex vivo (graft manipulation) 96 (8.6) 0
Prolonged neutropenia during month before transplant 
(PML count <500/μL for ≥7 d)
219 (19.6) 82 (85.0)
Rituximab therapy before auto-HSCT NA 367 (22.6)
Antibacterial prophylaxis during neutropeniac
 No 141 (12.6) 214 (13.2)
 Yes 977 (87.4) 1411 (86.8)
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, anti-
thymocyte globulin; auto-HSCT, autologous HSCT; HLA, human leukocyte antigen; NA, not 
applicable; PML, polymorphonuclear leukocyte.
aData represent No. (%) of patients unless otherwise specified.
bThe 352 transplants from HLA-mismatched related donors included 311 haploidentical 
transplants.
cA fluoroquinolone was used in 88% of allo-HSCT and 94% of auto-HSCT recipients who 
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E. coli in 1 patient, ceph-NS E. coli in 5, ceph-NS K. pneumoniae 
in 2, carba-NS K. pneumoniae in 4, E. cloacae complex in 1, and 
non-MDR P. aeruginosa in 3). A significantly increased risk of 
pre-engraftment GNB caused by the same species with the same 
susceptibility phenotype was documented in patients with a pre-
transplant GNB caused by ceph-NS/carba-S E.  coli, carba-NS 
K. pneumoniae, or non-MDR P. aeruginosa. Pretransplant GNB 
caused by ceph-S E. coli did not represent a risk for a posttrans-
plant infection by the same pathogen (Figure 2).
The rate of colonization by ceph-NS/carba-S E. coli, ceph-NS/
carba-S K.  pneumoniae, carba-NS K.  pneumoniae, and MDR 
P. aeruginosa and the rate of pre-engraftment infection accord-
ing to colonization are detailed in Table  5. Colonization by 
resistant gram-negative bacteria was always associated with a 
significantly increased risk of pre-engraftment infection by the 
same pathogen. In particular, a high probability of pre-engraft-
ment infection by the same colonizing species 30  days after 
HSCT was observed for carba-NS K. pneumoniae (32.5% in col-
onized vs 0.1% in noncolonized; P < .001) and MDR P. aerugi-
nosa (28.6% vs 0.6%; P < .001) (Figure 3A).
Survival
The overall survival 4 months after transplant was 86.3% (95% 
CI, 84.3%–88.4%). In multivariate analysis, acute leukemia, 
previous auto-HSCT, a disease not in complete remission at the 
time of HSCT, older age, prolonged pre-engraftment neutro-
penia, acute GVHD, and pre-engraftment GNB (hazard ratio, 
2.13; 95% CI, 1.45–3.13; P  <.001) were factors independently 
associated with increased mortality rate (Table 6).
The mortality rate 30  days after the diagnosis of GNB was 
17.9% (25 of 140 patients), and in 96% of patients (24 of 25) the 
infection was considered the primary cause of death. Of 46 
patients who died before engraftment, the cause of death was a 
GNB in 18 (39.1%).
The probability of survival 4 months after allo-HSCT in 978 
patients without any GNB was 88.3%, compared with 80.0% 
in 45 patients with ceph-S E. coli infection (P = .09), 86.7% in 
30 with ceph-NS E.  coli infection (P =  .73), 40.0% in 15 with 
carba-NS K. pneumoniae infection (P < .001), 61.5% in 13 with 
non-MDR P. aeruginosa infection (P = .001) and 25% in 8 with 
MDR P. aeruginosa infection (P < .001) (Figure 4).






No documented infection,  
No. of patients (%)
 No fever or documented infection 329 (29.5) 755 (46.5)
 Fever of unknown origin only 395 (35.3) 472 (29.0)
Clinically documented infections, No. of 
episodes/No. of patients (%)
68/67 (6.0) 87/85 (5.2)
 Pneumonia 39/39 (3.5) 53/53 (3.3)
 Skin infection 14/14 (1.2) 12/12 (0.7)
 GI tract infection 6/6 (0.5) 20/18 (1.1)
 Other 10/9 (0.8) 2/2 (0.1)
Microbiologically documented infections,  
No. of episodes/No. of patients (%)
412/331 (30.1) 355/320 (19.2)
 Gram-negative bacterial infection 157/148 (13.2)a  162/157 (9.7)b
 Gram-positive bacterial infection 209/193 (17.3) 182/172 (10.6)
 Fungal infection 24/24 (2.1) 9/9 (0.5)
 Viral infection 22/22 (2.0) 2/2 (0.1)
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, 
autologous HSCT; GI, gastrointestinal.
aIncluding 149 episodes of bacteremia in 140 patients plus 8 other site infections in 8 
patients.
bIncluding 151 episodes of bacteremia in 146 patients plus 11 other site infections in 11 
patients.
Table  3. Distribution of Gram-Negative Species and Antimicrobial 
Susceptibility Patterns





Escherichia coli, total No. (%) 77 (51.7) 92 (60.9)
 Ceph-S, carba-S, No. (% of E. coli) 46 (59.7) 63 (68.5)
 Ceph-NS, carba-S, No. (% of E. coli) 30 (39.0) 29 (31.5)
 Ceph-NS, carba-NS, No. (% of E. coli) 1 (1.3) 0
Klebsiella pneumoniae, total No. (%) 28 (18.8) 23 (15.2)
 Ceph-S, carba-S, No. (% of 
K. pneumoniae)
6 (21.4) 7 (30.4)
 Ceph-NS, carba-S, No. (% of 
K. pneumoniae)
6 (21.4) 10 (43.5)
 Ceph-NS, carba-NS, No. (% of 
K. pneumoniae)
16 (57.1) 6 (26.1)
Other Enterobacteriaceae, total No. (%) 9 (6.0)b 10 (6.6)c 
 Ceph-S, carba-S, No. (% of other 
Enterobacteriaceae)
8 (88.9) 10 (100)
 Ceph-NS, carba-S, No. (% of other 
Enterobacteriaceae)
0 0
 Ceph-NS, carba-NS, No. (% of other 
Enterobacteriaceae)
1 (11.1) 0
Pseudomonas aeruginosa, total No. (%) 21 (14.1) 13 (8.6)
 Non-MDR P. aeruginosa, No. (% of 
P. aeruginosa)
13 (61.9) 12 (92.3)
 MDR P. aeruginosa, No. (% of 
P. aeruginosa)
8 (38.1) 1 (7.7)
Other gram-negative bacteria, total No. (%) 14 (9.4)d 13 (8.6)e
 Non-MDR, No. (% of other gram–nega-
tive bacteria)
11 (78.6) 11 (84.6)
 MDR, No. (% of other gram-negative 
bacteria)
3 (21.4) 2 (15.4)
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, 
autologous HSCT; carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbap-
enems; ceph-NS, nonsensitive to the third-generation cephalosporin ceftazidime; ceph-S, 
sensitive to ceftazidime; MDR, multidrug-resistant.
aCarba-S was defined as a minimum inhibitory concentration ≤1 mg/L for imipenem, mero-
penem, and ertapenem; MDR, as resistance to ≥3 of the following antibiotics: ciprofloxa-
cin, amikacin, piperacillina-tazobactam, ceftazidime, meropenem, and imipenem.
 bIncluding Enterobacter spp. (6 cases), Klebsiella oxytoca (2 cases), and Serratia marc-
escens (1 case).
cIncluding Enterobacter spp. (5 cases), Morganella morganii (2 cases), and Proteus mirabi-
lis, Serratia marcescens, and Yersinia enterocolitica (1 case each).
dIncluding Stenotrophomonas maltophilia (3 cases), Acinetobacter spp. (3 cases), 
Pseudomonas spp. (4 cases), Capnocytophaga spp. (2 cases), Rhizobium radiobacter (1 
case), and Citrobacter spp. (1 case).
eIncluding Acinetobacter spp. (6 cases), Capnocytophaga spp. (2 cases), and Bacteroides 
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Auto-Hematopoietic Stem Cell Transplantation
Pre-engraftment Infections and Details on Gram-Negative 
Bacteremia
The infections documented before engraftment are detailed in 
Table 2. Overall, 151 GNBs were documented in 146 of 1625 
auto-HSCTs (9.0%). The rate of GNB by transplant center 
ranged from 0% to 33.1% (median, 7.5%). The median rate of 
GNB accounted for 6.0% in centers with lower transplant activ-
ity (≤23 HSCTs) and 8.6% in those with higher activity (>23 
HSCTs) (P = .93). E. coli was the most common gram-nega-
tive pathogen (92 cases; 60.9%), followed by K. pneumoniae (23 
cases, 15.2%) and P. aeruginosa (13 cases; 8.6%). The suscepti-
bility pattern of the isolates is detailed in Table 3.
Risk Factors for Gram-Negative Bacteremia in Auto-Hematopoietic 
Stem Cell Transplantation Recipients
The cumulative incidence of GNB 20 days after transplant was 
9.0% (95% CI, 8%–11%) (Figure 1B). GNB free pre-engraftment 
death occurred in 6 patients (0.4%). The risk of GNB according 
to demographics, underlying disease, and transplant variables 
are detailed in Table 4. By multivariate analysis, variables associ-
ated with pre-engraftment GNB were a diagnosis of lymphoma, 
older recipient age, and no antibacterial prophylaxis.
Risk of Gram-Negative Bacteremia by Species According to 
Pretransplant Infection and Colonization
A pretransplant infection by a gram-negative pathogen was 
reported in 39 patients (2.4%) (ceph-S E. coli in 7, ceph-NS/car-
ba-S E. coli in 5, ceph-S K. pneumoniae in 7, ceph-NS/carba-S 
K. pneumoniae in 2, carba-NS K. pneumoniae in 2, E. cloacae 
complex in 5, and other pathogens in 11). In only 3 patients was 
a posttransplant infection by the same pathogen documented 
(ceph-S E. coli, ceph-S K. pneumoniae, and carba-NS K. pneu-
moniae at 2, 7, and 7 days after transplant, respectively).
The rate of colonization by ceph-NS/carba-S E. coli, ceph-NS/
carba-S K.  pneumoniae, carba-NS K.  pneumoniae, and MDR 
P. aeruginosa and the rate of pre-engraftment infection accord-
ing to colonization are detailed in Table  5. A  significant cor-
relation between colonization and pre-engraftment infection 
by the same species 20 days after transplant was observed for 
ceph-NS/carba-S E.  coli (10.5% in colonized vs 4.5% in non-
colonized; P = .04), ceph-NS/carba-S K. pneumoniae (20.4% vs 
0.3%; P < .001), and carba-NS K. pneumoniae (19.0% vs 0.01%; 
P < .001) (Figure 3B).
Survival
The overall survival 4 months after auto-HSCT was 97% (95% 
CI, 96.2%–97.9%). In multivariate analysis, a diagnosis of 
lymphoma, prolonged neutropenia during the month before 
auto-HSCT, a disease not in complete remission at the time 
of transplant, prolonged pre-engraftment neutropenia, and 
pre-engraftment GNB (hazard ratio, 2.43; 95% CI, 1.22–4.84; 
P =  .01) were factors independently associated with increased 
mortality rates (Table 6). The mortality rate 30 days after GNB 
diagnosis was 4.1% (6 of 146 patients), and in all 6 patients GNB 
was considered the primary cause of death. Of 11 patients who 
died before engraftment, the cause of death was a GNB in 4 
(36.4%).
The probability of survival at 4  months after transplant in 
1479 patients without any GNB was 97.5%, compared with 
98.4% in 63 patients with ceph-S E.  coli infection (P  =  .66), 
93.1% in 29 with ceph-NS/carba-S E. coli infection (P =  .13), 
85.7% in 7 with ceph-S K.  pneumoniae infection (P  =  .04), 
90% in 10 with ceph-NS/carba-S K.  pneumoniae infection 
(P =  .14), 66.7% in 6 with carba-NS K. pneumoniae infection 
(P < .001), and 83.3% in 12 with non-MDR P. aeruginosa infec-
tion (P = .001).
Figure 1. Cumulative incidence curve for gram-negative bacteremia (GNB) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (A) and auto-HSCT (B) in 
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Table 4. Risk Factors of Gram Negative Bacteremia During the Pre-Engraftment Period According to Demographic, Underlying Disease, and Transplant Variables
Variables
Allo-HSCT Auto-HSCT
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value 
Sex
 Male 1.00 1.00
 Female 1.066 (.76–1.49) .71 0.95 (.68–1.33) .78
Age (increased by 10 y) 1.21 (1.10–1.33) <.001 1.16 (1.06–1.27) .001 1.09 (.99–1.22) .10 1.20 (1.06–1.36) .004
Underlying disease for allo-HSCT
 Acute leukemia 1.00 NA
 Other diseases 0.71 (.50–1.00) .05 0.65 (.46–.92) .01 NA
Underlying disease for auto-HSCT
 Multiple myeloma NA 1.00
 Lymphoma NA 1.51 (1.07–2.13) .03 1.86 (1.30–2.66) <.001
 Acute leukemia NA 1.71 (.83–3.52) .14 1.86 (.90–3.86) .09
 Other diseases NA 1.18 (.60–2.29) .63 2.36 (1.06–5.26) .04
Phase of underlying disease at transplant
 Complete remission 1.00 1.00
 No complete remission 1.23 (.88–1.72) .22 1.13 (.81–1.57) .47
Previous auto-HSCT
 No 1.00 .93 1.00
 Yes 0.98 (.64–1.50) 0.88 (.59–1.33) .56
Previous allo-HSCT
 No 1.00 NA
 Yes 1.04 (.60–1.80) .89 NA
Pretransplant neutropenia
 No 1.00 1.00
 Yes 1.11 (.74–1.65) .62 1.08 (.53–2.20) .84
Pretransplant rituximab
 No NA 1.00
 Yes NA 1.58 (1.11–2.25) .01
Stem cell source
 Peripheral blood 1.00 NA
 Bone marrow 1.68 (1.19–2.36) .003 NA
 Cord blood 2.46 (1.06–5.70) .04 NA
Donor type
 Matched related 1.00 NA
 Mismatched related 4.21 (2.37–7.49) <.001 4.14 (2.31–7.42) <.001 NA
 Matched unrelated volunteer 2.01 (1.05–3.82) .03 1.68 (.87–3.25) .12 NA
 Mismatched unrelated volunteer 3.53 (1.81–6.87) <.001 2.92 (1.47–5.81) .002 NA
 Cord blood 4.95 (1.89–12.94) .001 3.50 (1.32–9.29) .01 NA
Conditioning regimen
 Myeloablative 1.00 NA
 Nonmyeloablative/reduced intensity 1.83 (1.31–2.56) <.001 NA
T-cell depletion
 No 1.00 NA
 Yes, ATG in vivo 1.03 (0.73–1.46) .85 NA
 Yes, manipulation ex vivo 0.16 (.04–.67) .01 0.13 (.03–.53) .004 NA
Antibacterial prophylaxis
 No 1.00 1.00
 Yes 0.71 (.45–1.12) .14 0.52 (.35–.77) .001 0.50 (.34–.75) <.001
Acute GVHD during engraftment
 Grade 0–I 1.00 NA
 Grade II–IV 1.25 (0.32–4.81) .75 NA
Duration of pre-engraftment neutropenia
 PML count <500/μL 1.02 (1.01–1.03) <.001 1.03 (1.008–1.052) <.001
 PML count <100/μL 1.03 (1.02–1.04) <.001 1.02 (1.01–1.03) <.001 1.03 (1.01–1.06) .003
Mucositis
 CTC grade 0–I 1.00 1.00
 CTC grade II–IV 1.47 (.74–1.47) .79 1.17 (.84–1.62) .35
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocyte globulin; auto-HSCT, autologous HSCT; CI, confidence interval; CTC, common toxicity 
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DISCUSSION
The emergence of infections by gram-negative bacteria resist-
ant to antibiotics has become a public health problem of major 
concern worldwide [12–14]. However, in HSCT populations, 
information regarding the current incidence and prognos-
tic factors of gram-negative infections and their antibiotic 
resistance patterns is mainly limited to retrospective, sin-
gle-center experiences [7, 15–25]. The GITMO-AMCLI-
SIGNB survey, which included 64% of allo-HSCTs and 51% of 
auto-HSCTs performed in Italy in 2014, is a prospective study 
designed to critically assess the incidence and risk factors of 
GNB during the pre-engraftment period, and their impact on 
Figure 2. Risk of pre-engraftment gram-negative bacteremia (GNB) recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) according to pretrans-
plant GNB caused by the same species with the same susceptibility phenotype. (The risk was not calculated for other pathogens, for which the rates of pretransplant GNB 
were very low.) Abbreviations: Carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbapenems; ceph-NS, nonsensitive to the third-generation cephalosporin cef-
tazidime; ceph-S, sensitive to ceftazidime; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; MDR, multidrug-resistant; P. aeruginosa, Pseudomonas aeruginosa.
Table 5. Correlation Between Rectal Colonization by Resistant Gram-Negative Bacteria and Pre-Engraftment Gram Negative Bacteremia Caused by a 













Ceph-R/carba-S Escherichia Coli 69/909 (7.6) 8.7/1.3 (.001) 89/1307 (6.8) 9.0/4.3 (.06)
Ceph-R/carba-S Klebsiella 
pneumoniae
14/909 (1.5) 7.1/0.4 (.07) 21/1307 (1.6) 19.0/0.3 (<.001)
Carba-R K. pneumoniae 36/1058 (3.4) 27.8/0.4 (<.001) 21/1432 (1.5) 19.0/0.007 (<.001)
MDR Pseudomonas aeruginosa 7/897 (0.8) 28.6/0.6 (.001) 2/1307 (0.15) 50/0.007 (.003)
Abbreviations: Allo-HSCT and auto-HSCT, allogeneic and autologous hematopoietic stem cell transplantation; carba-R, resistant to carbapenems; carba-S, sensitive to carbapenems; ceph-R, 
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patient outcome. A valuable characteristic of this study was the 
availability of complete prospectively collected denominator 
data.
The overall pre-engraftment cumulative incidence of GNB 
was 17.3% at 30 days after allo-HSCT and 9% at 20 days after 
auto-HSCT. E. coli, K. pneumoniae, and P. aeruginosa were the 
Figure 3. Risk of pre-engraftment gram-negative bacteremia (GNB) according to colonization by resistant GNB in allogeneic hematopoietic stem cell transplantation (allo-
HSCT) (A) and autologous HSCT (auto-HSCT) (B) recipients. The risk was not calculated for other resistant pathogens, for which the rates of colonization were very low.) 
Abbreviations: Carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbapenems; ceph-NS, nonsensitive to the third-generation cephalosporin ceftazidime; E. coli, 
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most common isolates in both transplant procedures. In auto-
HSCT, the rates of ceph-NS and carba-NS isolates in E. coli and 
K. pneumoniae and the MDR rate in P. aeruginosa were similar 
to those reported in the general Italian hospitalized population 
[14]. Conversely, in allo-HSCT recipients the rates of resistance 
were significantly higher; ceph-NS isolates accounted for about 
40% of E. coli and 78% of K. pneumoniae isolates and carba-NS 
isolates for 57% of K. pneumoniae, and MDR was detected in 
about 38% of P.  aeruginosa isolates. The hospitalizations and 
exposition to multiple antibiotics courses during the pretrans-
plant period presumably justify the greater selection of microor-
ganisms with reduced susceptibility phenotypes in allo-HSCT.
We found that diagnosis of acute leukemia, a transplant from 
an HLA-mismatched donor (related or unrelated) and cord blood, 
older recipient age, and prolonged neutropenia were independent 
risk factors of for-engraftment GNB in allo-HSCT. Conversely, ex 
Table 6. Probability of Death Within 4 Months After Transplant
Variables
Allo-HSCT Auto-HSCT
Univariate Multivariate Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value 
Female vs male sex 0.82 (.59–1.14) .24 0.78 (.43–1.41) .40
Age (increased by 10 y) 1.15 (1.06–1.25) .001 1.10 (1.01–1.20) .03 0.99 (.83–1.18) .90
Underlying disease for allo-HSCT, NA
 Acute leukemia 1.00
 No acute leukemia 0.81 (.59–1.12) .21 0.42 (.28–.63) <.001
Underlying disease for auto-HSCT NA
 Multiple myeloma 1.00
 Lymphoma 5.1 (2.44–10.7) <.001 6.17 (2.78–13.6) <.001
 Acute leukemia 3.01 (.65–13.94) .16
 Other diseases 4.1 (1.38–12.3) .01 4.77 (1.24–18.3) .02
Complete remission of underlying 
disease at transplant, no vs yes
1.82 (1.32–2.51) <.001 2.16 (1.47–3.15) <.001 3.55 (1.7–7.6) .001 4.8 (2.19–10.34) <.001
Prior auto-HSCT, yes vs no 1.43 (.10–2.06) .051 1.76 (1.18–2.63) <.001 0.86 (.41–1.77) .68
Prior allo-HSCT, yes vs no 1.60 (1.01–2.54) .04 NA
Pretransplant neutropenia, yes vs no 1.34 (.93–1.94) .12 5.2 (2.6–10.5) <.001 3.82 (1.80–8.12) <.001
Pretransplant rituximab, yes vs no NA 2.9 (1.7–5.2) <.001
Stem cell source NA
Bone marrow vs Peripheral 1.10 (.79–1.53) .55
Cord blood vs peripheral 1.93 (.89–4.19) .09
Donor type NA
Mismatched related vs matched 
related
1.93 (1.25–2.97) .003
Matched unrelated volunteer vs 
matched related
1.19 (.73–1.93) .48
Mismatched unrelated volunteer vs 
matched related donor
1.11 (.60–2.03) .74 
Cord blood vs matched related 2.51 (1.10–5.71) .03
Nonmyeloablative/reduced intensity 
vs myeloablative conditioning
1.55 (1.11–2.16) .01 NA
T-cell depletion NA
In vivo ATG vs no T-cell depletion 1.04 (.74–1.46) .82
Ex vivo manipulation vs no T-cell 
depletion
1.0 (.26–1.79) .99
Antibacterial prophylaxis, yes vs no 0.76 (.49–1.17) .21 1.31 (.52–3.31) .57
Mucositis, CTC grade II–IV vs CTC 
grade 0–I
0.94 (.68–1.31) .73 1.36 (.76–2.44) .30
Duration of pre-engraftment 
neutropenia
PML count <500/μL 1.02 (1.01–1.04) <.001 1.09 (1.06–1.12) <.001
PML count <100/μL 1.03 (1.02–1.04) <.001 1.03 (1.01–1.04) <.001 1.09 (1.07–1.12) <.001 1.07 (1.04–1.18) <.001
Acute GVHD, grade II–IV vs grade 0–I 2.07 (1.17–3.65) .01 2.15 (1.21–3.82) .009 …
Gram-negative bacterial infection, 
yes vs no
2.99 (2.08–4.31) <.001 2.13 (1.45–3.13) <.001 3.16 (1.61–6.19) <.001 2.43 (1.22–4.84) .01
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocyte globulin; auto-HSCT, autologous HSCT; CI, confidence interval; CTC, common toxicity 
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vivo T-cell depletion was protective, presumably related to the ear-
lier engraftment and lower rate of early posttransplant complica-
tions (ie, GVHD), which characterize certain graft manipulations 
[26]. In the setting of auto-HSCT, a diagnosis of lymphoma, older 
age, and no antibacterial prophylaxis were predictive of GNB. 
It is of interest that fluoroquinolone prophylaxis had different 
effects in the 2 transplant populations; it halved the rate of GNB 
after auto-HSCT but had no impact in allo-HSCT. Whether anti-
bacterial prophylaxis is still indicated in neutropenic patients in 
an era of antibiotic resistance is a debated issue, and some centers 
no longer administer it given the high rate of fluoroquinolone 
resistance and the possible negative impact of prophylaxis in the 
selection of resistant intestinal flora [27–29]. Our data suggest 
that in high-risk patients with a history of antimicrobial pres-
sure, like those undergoing allo-HSCT, fluoroquinolone proph-
ylaxis is no longer protective, at least against GNB. However, 
low-risk patients not receiving antibiotic treatment—for exam-
ple, patients with multiple myeloma who receive auto-HSCT 
immediately after nonintensive remission induction therapy—
still seem to benefit from selective intestinal decontamination 
with fluoroquinolones during neutropenia. Our data are in 
agreement with those reported earlier in neutropenic patients 
with multiple myeloma undergoing auto-HSCT [30].
Pretransplant infection in allo-HSCT and colonization by resist-
ant gram-negative bacteria in both allo- and auto-HSCT were 
highly predictive of a pre-engraftment infection by a pathogen with 
the same susceptibility phenotype [6]. Absent molecular character-
ization of the isolates, we could not demonstrate whether the same 
pathogen was responsible for both the pretransplant infection or 
colonization and the posttransplant GNB; however, this correlation 
seems highly reliable in the majority of cases. Indeed, the high rate 
of early infection relapses observed in allo-HSCT recipients with 
a pretransplant infection by a resistant pathogen may suggest the 
failure of previous antibiotic treatment to eradicate the infection, 
particularly by carba-NS pathogens. The predictive role of pre-
transplant infection and colonization in certain MDR infections 
may have relevance in the definition of the infection-control strat-
egies and the selection of patients or conditions deserving tailored 
front-line treatments with old and new antibiotics [5, 8, 9, 31, 32].
Overall, the mortality rate 4 months after transplant was 13.7% 
for allo-HSCT and 3% for auto-HSCT. In addition to the well-
known factors predicting poor outcome (in allo-HSCT: acute 
leukemia, previous auto-HSCT, disease not in complete remission 
at the time of transplant, older recipient age, prolonged pre-en-
graftment neutropenia, acute GVHD; in auto-HSCT: a lymphoma 
diagnosis, prolonged neutropenia during the month before trans-
plant, disease not in complete remission at the time of transplant, 
and prolonged pre-engraftment neutropenia), GNB represented 
an independent prognostic factor in both populations and GNB 
was the cause of death in 39.1% of allo-HSCT recipients and 36.4% 
of auto-HSCT recipients who died before engraftment. The poor 
prognostic impact of GNB was related mainly to infections by 
carba-NS enterobacteria and by P.  aeruginosa, regardless of the 
susceptibility pattern, whereas the outcome in patients infected 
by carba-S enterobacteria did not differ significantly from that in 
patients who did not experience any GNB [33]. This finding fur-
ther underlines the importance of early tailored treatment strate-
gies in patients at risk of infections by MDR pathogens [5, 6, 8, 9].
In conclusion, our study identifies incidence and risk factors 
for pre-engraftment GNB in a real-life HSCT scenario. It confirms 
that the phenomenon of antimicrobial resistance is relevant, par-
ticularly in allo-HSCT recipients, and dramatically affects overall 
outcome. Previous infectious history and colonization monitor-
ing represent major indicators of the GNB risk. The results of the 
present study may be useful to identify HSCT subpopulations 
who might benefit from targeted antibiotic treatments, and they 
underline the crucial importance of continuous epidemiological 
monitoring in defining appropriate infection-control strategies.
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